Kangji Medical Holdings Limited

HKSE 9997.HK

Kangji Medical Holdings Limited EBITDA Margin for the year ending December 31, 2023: 50.17%

Kangji Medical Holdings Limited EBITDA Margin is 50.17% for the year ending December 31, 2023, a -32.75% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Kangji Medical Holdings Limited EBITDA Margin for the year ending December 31, 2022 was 74.60%, a 20.53% change year over year.
Kangji Medical Holdings Limited EBITDA Margin for the year ending December 31, 2021 was 61.90%, a -0.80% change year over year.
Kangji Medical Holdings Limited EBITDA Margin for the year ending December 31, 2020 was 62.39%, a -9.00% change year over year.
Kangji Medical Holdings Limited EBITDA Margin for the year ending December 31, 2019 was 68.56%, a -9.32% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

HKSE: 9997.HK

Kangji Medical Holdings Limited

CEO	Mr. Ming Zhong
IPO Date	June 29, 2020
Location	China
Headquarters	Tonglu Economic Development Zone
Employees	964
Sector	Health Care
Industries Medical Instruments Pharmaceuticals

Description

Kangji Medical Holdings Limited, through its subsidiaries, designs, develops, manufactures, and sale of minimally invasive surgical instruments and accessories in China. It offers disposable trocars, polymer ligation clips, disposable electrocoagulation forceps, ultrasonic scalpels, and other types of disposable hand-held instruments; and reusable trocars, reusable forceps, and other reusable products. The company's products are used in obstetrics and gynecology, general surgery, urology, and thoracic surgery specialties. It primarily sells products to a network of distributors. The company was founded in 2004 and is headquartered in Hangzhou, China.

Key trends

Past 5 years